How targeted alpha, actinium-225, lutetium-177, and next-gen radioligand-therapy startups raise capital in 2026 amid Novartis, Lilly.
Radioligand therapy is the hottest oncology modality of the decade. Novartis Pluvicto and Lutathera crossed a combined $2B+ annual run rate. Big pharma bought aggressively: Novartis→Endocyte→AAA→Mariana Oncology ($1B) and iTheranostics; Eli Lilly→POINT Biopharma ($1.4B); BMS→RayzeBio ($4.1B); AstraZeneca→Fusion Pharmaceuticals ($2.4B); Sanofi→Orano Med JV. Actinium-225 supply, cyclotron access, and cold-chain logistics defined the moats. Perspective Therapeutics, Aktis, Convergent, Ratio Therapeutics, Nucleus RadioPharma, and Precirix raised on next-gen isotopes and vector chemistry. Investors want a differentiated target × isotope combination, secured isotope supply (Ac-225, Pb-212, Cu-67, At-211), and clinical package with a clear registrational path.
Pluvicto's PSMA-lutetium franchise validated the modality with a >$1B run rate and pending mCSPC expansion. Big-pharma M&A totaled >$10B across POINT, RayzeBio, Fusion, and Mariana. Ac-225 (targeted alpha) emerged as the next wave — more potent per decay, shorter path length, less normal-tissue toxicity. TerraPower Isotopes, Niowave, Bruce Power/BWXT, and Fusion's Canadian JV scaled Ac-225 supply. FDA Center for Drug Evaluation and Research issued draft guidance on radiopharmaceutical clinical development. CMS payment codes stabilized for hospital outpatient administration. Nucleus RadioPharma and Cardinal Nuclear scaled hub-and-spoke US manufacturing footprint.
Seed: $10-40M for target validation + first radiolabel. Series A: $40-120M for IND + Phase 1. Series B: $100M-$300M for Phase 1b/Phase 2 + isotope supply. Series C/crossover: $150M-$500M for pivotal-enabling. Reference: Perspective Therapeutics (public, ~$800M), Aktis Oncology ($144M B), Convergent Therapeutics ($90M B), Ratio Therapeutics ($100M+ raised), Nucleus RadioPharma ($56M A), Precirix ($100M+ raised). Consolidation is fast: strategic acquisitions have hit $1-4B at Phase 1b/Phase 2.
No secured isotope supply — Ac-225 shortage is a hard binding constraint. Underestimating radiochemistry and cGMP radiopharm manufacturing complexity. Weak dosimetry package. Ignoring salivary/renal/hematologic dose-limiting toxicities. No hub-and-spoke manufacturing plan. Racing Novartis/Lilly/BMS with a me-too PSMA-Lu asset. Underestimating regulatory complexity (both FDA CDER and NRC/state radioactive-materials licensing).
Investor directory · Fundraising library · Articles A–Z · Company funding database